Research News

Rivaroxaban prophylaxis too risky for medical inpatients

BMJ 2013; 346 doi: (Published 13 February 2013) Cite this as: BMJ 2013;346:f875

OpenUrlCrossRefPubMedWeb of Science

Medical inpatients who need thromboprophylaxis usually stop treatment when they go home, but the manufacturers of the oral anticoagulant rivaroxaban have been investigating the risks and benefits of extending treatment from the usual 10 days to 35 days. The overall balance did not look favourable …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to to receive unlimited access to all content on for 14 days.
Sign up for a free trial